Capstone Financial Advisors Inc. Has $299,000 Stock Position in Eli Lilly and Company $LLY

Capstone Financial Advisors Inc. grew its position in Eli Lilly and Company (NYSE:LLY) by 15.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 384 shares of the company’s stock after purchasing an additional 52 shares during the period. Capstone Financial Advisors Inc.’s holdings in Eli Lilly and Company were worth $299,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Willner & Heller LLC raised its position in Eli Lilly and Company by 1.5% during the first quarter. Willner & Heller LLC now owns 854 shares of the company’s stock valued at $705,000 after acquiring an additional 13 shares in the last quarter. Braun Bostich & Associates Inc. grew its position in Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock worth $411,000 after acquiring an additional 13 shares in the last quarter. Rise Advisors LLC increased its stake in shares of Eli Lilly and Company by 1.8% during the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company’s stock worth $571,000 after purchasing an additional 13 shares during the last quarter. Occidental Asset Management LLC raised its holdings in shares of Eli Lilly and Company by 0.7% during the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after purchasing an additional 13 shares in the last quarter. Finally, New Insight Wealth Advisors lifted its stake in shares of Eli Lilly and Company by 3.4% in the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock valued at $307,000 after purchasing an additional 13 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LLY has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. JPMorgan Chase & Co. reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. Cantor Fitzgerald increased their price target on Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Finally, HSBC lifted their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $999.32.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,022.00 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business’s 50 day moving average is $820.93 and its two-hundred day moving average is $779.85. The company has a market cap of $966.19 billion, a P/E ratio of 66.80, a P/E/G ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,032.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.